New malaria cocktail aims to knock out relapsing p. vivax
NCT ID NCT07533136
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining tafenoquine with different antimalarial drugs can better prevent P. vivax malaria from coming back. About 300 adults in Thailand with uncomplicated P. vivax infection will receive one of three drug pairs and be monitored for 6 months. The goal is to find a more effective radical cure that reduces relapse rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tafenoquine (with chloroquine, dihydroartemisinin-piperaquine, or artemether-lumefantrine)
- What this could lead to
- If successful, this could identify a more effective drug combination to prevent P. vivax malaria from coming back after treatment.
- What could go wrong
- This is an early-stage trial with only 300 participants, so results may not apply broadly. The study has not yet started recruiting, and the drugs may cause side effects or fail to prevent relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCOMPLICATED P. VIVAX MONO-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tha Song Yang Hospital
Ratchathewi, Bangkok, 10400, Thailand